Cytek Biosciences Inc (CTKB)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 56.69% | 57.75% | 60.05% | 61.32% | 61.56% | 61.41% | 60.17% | 60.93% |
| Operating profit margin | -14.43% | -15.09% | -11.30% | -6.99% | -1.10% | -0.37% | 0.65% | 4.07% |
| Pretax margin | -8.14% | -8.58% | -5.51% | -2.70% | 0.77% | -1.55% | -1.47% | 1.78% |
| Net profit margin | -6.29% | -7.61% | -3.33% | -1.30% | 1.51% | -1.55% | -1.75% | 0.55% |
Cytek Biosciences Inc experienced fluctuations in its profitability ratios over the past eight quarters. The gross profit margin, which indicates the efficiency of production and pricing strategies, decreased from 61.56% in Dec 2022 to 56.69% in Dec 2023, indicating a potential decline in profitability from sales.
The operating profit margin, a measure of a company's operating efficiency, saw a downward trend from 4.07% in Mar 2022 to -14.43% in Dec 2023, suggesting that the company's operating expenses may have been higher relative to its revenue in recent quarters.
The pretax margin, reflecting the company's ability to generate profits before taxes, fluctuated from -1.55% in Sep 2022 to -8.14% in Dec 2023. This indicates that Cytek Biosciences Inc faced challenges in controlling its expenses and maintaining profitability before accounting for taxes.
Furthermore, the net profit margin, which measures the company's bottom-line profitability after all expenses have been deducted, swung from -1.75% in Jun 2022 to -7.61% in Sep 2023. This suggests that Cytek Biosciences Inc may have experienced difficulties in generating profits from its core business operations during these periods.
Overall, the fluctuating profitability ratios of Cytek Biosciences Inc highlight potential challenges in managing costs, maintaining sales revenue, and achieving profitability over the past eight quarters.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -5.63% | -5.32% | -3.78% | -2.21% | -0.35% | -0.11% | 0.20% | 1.17% |
| Return on assets (ROA) | -2.46% | -2.68% | -1.11% | -0.41% | 0.48% | -0.48% | -0.53% | 0.16% |
| Return on total capital | -5.37% | -3.89% | -1.71% | -0.43% | 0.90% | -0.01% | -0.00% | 1.09% |
| Return on equity (ROE) | -3.09% | -3.35% | -1.38% | -0.51% | 0.58% | -0.58% | -0.63% | 0.19% |
Cytek Biosciences Inc's profitability ratios have shown a mixed performance over the past eight quarters.
- Operating return on assets (Operating ROA) has been consistently negative, indicating that the company is not efficiently generating profits from its assets. The trend shows a deterioration from a low of -0.35% in December 2022 to -5.63% in December 2023.
- Return on assets (ROA) has also been negative overall, but with less volatility compared to Operating ROA. The trend fluctuates around the zero mark, moving from 0.48% in December 2022 to -2.46% in December 2023.
- Return on total capital has shown a similar negative trend, with the company failing to generate sufficient returns from its total invested capital. The ratio decreased from 0.90% in March 2022 to -5.37% in December 2023.
- Return on equity (ROE) has been consistently negative as well, indicating that the company is not efficiently utilizing shareholder equity to generate profits. The trend has steadily decreased from 0.58% in March 2022 to -3.09% in December 2023.
Overall, Cytek Biosciences Inc's profitability ratios reflect financial challenges, with a persistent negative trend indicating inefficiency in utilizing assets, capital, and equity to generate profits. The company may need to undertake strategic initiatives to improve its profitability and operational efficiency.